CXCR4 and acute lymphoblastic leukemia: These findings suggest that these increases in surface CXCR4 are functional and that plerixafor-treated ALL blasts may have the potential to have increased interactions with the bone marrow microenvironment, highlighting a possible mechanism of resistance to CXCR4 inhibition.